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Abstract
Purpose Sipuleucel-T, the ﬁrst FDA-approved autolo-
gous cellular immunotherapy for treatment of advanced
prostate cancer, is manufactured by activating peripheral
blood mononuclear cells, including antigen presenting cells
(APCs), with a fusion protein containing prostatic acid
phosphatase. Analysis of data from three phase 3 trials was
performed to immunologically characterize this therapy
during the course of the three doses, and to relate the
immunological responses to overall survival (OS).
Methods Sipuleucel-T product characteristics [APC
numbers, APC activation (CD54 upregulation), and total
nucleated cell (TNC) numbers] were assessed in three
randomized, controlled phase 3 studies (N = 737). Anti-
gen-speciﬁc cellular and humoral responses were assessed
in a subset of subjects. The relationships between these
parameters and OS were assessed.
Results APC activation occurred in the ﬁrst dose prepa-
ration [6.2-fold, (4.65, 7.70); median (25th, 75th
percentile)] and increased in the second [10.6-fold (7.83,
13.65)] and third [10.5-fold (7.89, 13.65)] dose prepara-
tions. Cytokines and chemokines associated with activated
APCs were produced during the manufacture of each dose;
T-cell activation-associated cytokines were detected in the
second and third dose preparations. Antigen-speciﬁc T
cells were detectable after administration of the ﬁrst sipu-
leucel-T dose. Cumulative APC activation, APC number,
and TNC number correlated with OS (P\0.05). Antigen-
speciﬁc immune responses were observed in 78.8 % of
monitored subjects and their presence correlated with OS
(P = 0.003).
Conclusion Sipuleucel-T broadly engages the immune
system by activating APCs ex vivo and inducing long-lived
immune responses in vivo. These data indicate antigen-
speciﬁc immune activation as a mechanism by which
sipuleucel-T prolongs OS.
Keywords Prostate cancer  Cellular  Humoral 
Immunotherapy  Survival
Introduction
Immunotherapy has long held the promise of controlling
cancer; however, attempts to translate immunotherapeutic
strategies into practice have been unsuccessful prior to the
2010 FDA approval of the autologous cellular immuno-
therapy, sipuleucel-T, in patients with asymptomatic or
minimally symptomatic metastatic castration-resistant
prostate cancer (mCRPC) [1–4]. Each dose of sipuleucel-T
is manufactured by culturing an individual’s own freshly
isolated peripheral blood mononuclear cells (PBMCs),
including antigen presenting cells (APCs) and T cells, with
a fusion protein (PA2024) composed of prostatic acid
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DOI 10.1007/s00262-012-1317-2phosphatase (PAP; an antigen expressed in prostate ade-
nocarcinoma [5, 6]) linked to granulocyte–macrophage
colony-stimulating factor (GM-CSF; an APC activator [7,
8]). A course of therapy consists of three doses of sipu-
leucel-T administered at two-week intervals. Before infu-
sion, each dose of sipuleucel-T is tested to ensure that it
meets quality standards, including assessments of both cell
viability and potency, by quantifying the number of APCs
and the activation of these cells. Thus, the preparation of
each sipuleucel-T dose provides an opportunity to immu-
nologically characterize this autologous cellular immuno-
therapy as it develops over the course of the three doses.
Previous studies have shown low levels of basal
immune response to PAP in prostate cancer patients [9–
11], which were augmented following immunization [12,
13, 16]; however, the studies were not sufﬁcient in size to
explore correlations with overall survival (OS). In three
phase 3, double-blind, placebo-controlled studies in sub-
jects with mCRPC [14–16], treatment with sipuleucel-T
prolonged OS, providing a unique opportunity to analyze
how the product parameters that were assessed on each
dose of sipuleucel-T, as well as peripheral immune
responses that were monitored in a subset of these sub-
jects, related to OS.
Materials and methods
Trial design and participants
The phase 3 trials IMPACT (n = 512) and D9901/D9902A
(n = 225) were randomized, double-blind, multicenter
studies of men with mCRPC randomized 2:1 to receive
sipuleucel-T or control [14–16]. Sipuleucel-T product
parameters were evaluated in all patients who received at
least one infusion. In order to allow a detailed examination
of the immune response to sipuleucel-T treatment, the
IMPACT trial was amended to allow further characteriza-
tion of the sipuleucel-T product in doses prepared at the
primary manufacturing facility (Seattle, WA, USA), and to
require peripheral immune response sampling at all clinical
study sites. Thus, further detailed immunological charac-
terization of the sipuleucel-T product was performed in a
subset of consented IMPACT patients with available pre-
culture cells (N = 20) and post-culture supernatants
(N = 49) during the treatment phase. Peripheral immune
responses were measured in a subset of consented subjects
enrolled in the IMPACT study (N = 237). The studies
were conducted in accordance with applicable regulations
of the FDA and the Good Clinical Practice guidelines of
the International Conference on Harmonisation and
approved by the institutional review board at each study
center.
Treatment
Details of the manufacture of sipuleucel-T have been pre-
viously described [14–17]. In brief, sipuleucel-T was pre-
pared by culturing freshly obtained leukapheresis PBMCs
with PA2024 for 36–44 h at 37 C. Control was prepared
by culturing approximately one-third of PBMCs without
PA2024; the remainder of the cells was cryopreserved for
possible use following disease progression to manufacture
a salvage treatment manufactured according to the same
speciﬁcations as sipuleucel-T. Subjects received sipuleu-
cel-T or control as an intravenous infusion over 30–60 min,
approximately every 2 weeks for a total of three infusions.
Product parameters
APC activation, APC number, and total nucleated cell
(TNC) count were determined for every sipuleucel-T and
control product as previously described [18], with APCs
deﬁned as large cells expressing CD54. APC activation
was measured as the increase in surface CD54 on APCs,
expressed as an upregulation ratio of the average number of
molecules on post-culture versus pre-culture cells. Cumu-
lative product parameters were deﬁned as the sum of the
values across the 3 treatment doses.
Immunological characterization of the product
T-cell proliferation and interferon gamma (IFNc) enzyme-
linked immunosorbent spot (ELISPOT) were evaluated at
treatment weeks 0, 2, and 4 for IMPACT subjects with
remaining pre-culture cells (Supplementary Figure 1).
Chemokines and cytokines were also measured in available
post-culture supernatants of IMPACT subjects (Supple-
mentary Figure 1).
Cellular proliferation
T-cell proliferation to PA2024 and PAP was assayed using
a standard tritiated thymidine (
3H-thymidine) incorporation
assay [19]. The degree of proliferation was expressed as a
stimulation index (SI), deﬁned as
3H-thymidine incorpo-
ration in the presence of antigen divided by
3H-thymidine
incorporation with media alone.
IFNc ELISPOT
IFNc ELISPOT assays were performed using polyvinyli-
dene ﬂuoride ELISPOT plates (Millipore, Billerica, MA,
USA) and anti-human IFNc antibodies (clone D1K and B6-
1, MabTech, Upsala, Sweden) per the manufacturers’
instructions. ELISPOT data are presented as the median of
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123triplicates with background (PBMCs incubated with media)
IFNc spots subtracted.
Ex vivo cytokine analysis
Ex vivo culture supernatant was analyzed for chemokine
and cytokine content via Luminex assay (Biosource,
Invitrogen Corp. Camarillo, CA, USA) or using a
Mesoscale Discovery Sector Imager 2400 (Gaithersburg,
MD, USA). In a subset of samples, pre-culture cells at
each treatment week were cultured with recombinant
GM-CSF (Leukine
 [sargramostim], Genzyme) and the
culture medium was then assayed using the Mesoscale
platform.
Long-term peripheral immune responses
A subset of patients enrolled in IMPACT consented to
provide blood for immune response determination at
baseline (week 0) as well as 6, 14, and 26 weeks following
the ﬁrst infusion (100 mL maximum at each time point;
Supplementary Figure 1); samples were processed within
24 h of collection. A 10-mL sample of blood was collected
in coagulant-free tubes for serum isolation; the remainder
was collected in sodium heparin-coated tubes to isolate
PBMCs as described previously [17] and cryopreserved
until batch assayed.
The T-cell proliferation and IFNc ELISPOT assays were
performed as described above. Sera were evaluated for the
presence of antigen-speciﬁc antibodies via an initial
enzyme-linked immunosorbent assay (ELISA) screening
assay. ELISAs were performed for each serum sample in
triplicate, and the geometric mean of the reciprocal of the
dilution that yielded an optical density equivalent to assay
background was reported.
Positive thresholds for treatment-related immune
responses were selected in order to ensure that \5%o f
subjects would exceed the value at baseline. Thresholds
were: proliferation, SI[12 for PA2024,[8 for PAP; IFNc
ELISPOT (per 3 9 10
5 PBMC), [10 spots for PA2024,
[40 spots for PAP; ELISA titer, [400 for both anti-
PA2024 and anti-PAP antibodies. Serum samples that gave
a positive response to an initial ELISA were subsequently
evaluated for IgM and IgG antibody isotypes.
Statistical analysis
T-cell proliferation and IFNc ELISPOT were compared
between groups using a t-test on the log-transformed
median SI values and ranked median ELISPOT values.
Antibody responses were compared between treatment
groups using a Wilcoxon rank sum test of the antibody
titers. Differences in T cell and antibody responder
frequencies were compared between treatment groups
using a Fisher’s exact test.
The correlation between OS and key cumulative product
parameters was examined using a Cox regression model,
with and without adjustment for baseline PSA and LDH
[14–16, 20, 21]. Each of the parameters was log trans-
formed, and the analysis was stratiﬁed by study. The cor-
relation between OS and peripheral immune response
responder status was examined using a Cox regression
model, with and without adjustment for baseline PSA and
LDH. All P values reported are two-tailed. No adjustment
for multiplicity of endpoints or time points was made.
Results
Subjects and treatment
Of the 737 subjects randomized in the IMPACT, D9901,
and D9902A studies, 476 received sipuleucel-T and 243
received control product, both with a median cell viability
of[95 % across all 3 infusions. For the subset of subjects
from IMPACT who provided blood for peripheral
immune response determinations (n = 160 sipuleucel-T;
n = 77 control), demographics and baseline disease
characteristics were balanced between study arms and
between the evaluated subgroup and the overall study
population (Table 1).
Product parameters and analyses of antigen-speciﬁc
T cells in the product
The sipuleucel-T ﬁnal product (IMPACT only) comprised
(median [25th, 75th percentile]): CD3
? T cells (62.3 %
[51.8, 69.1 %]), APCs (18.3 % [12.3, 26.5 %], the majority
of which were CD14
?), CD56
? NK cells (11.0 % [6.9,
15.3 %]), and CD19
? B cells (4.7 % [2.6, 7.9 %]). The
relative proportions of these cell types did not change
across the treatment weeks.
Product parameters
In both the IMPACT and D9901/D9902A studies, APC
activation was signiﬁcantly greater with sipuleucel-T rel-
ative to control at weeks 0, 2, and 4 (Fig. 1). For sipu-
leucel-T, median [25th, 75th percentile] APC activation
increased 6.2-fold [4.7, 7.7] in the ﬁrst product, compared
with 10.6-fold [7.8, 13.7] in the second and 10.5-fold [7.9,
13.7] in the third products (both P\0.001 vs. ﬁrst product,
all studies pooled). The median cumulative APC activation
with sipuleucel-T across the three dose preparations was
26.7 [21.5, 33.6]. TNC counts and number of APCs were
consistent and not signiﬁcantly different between doses
Cancer Immunol Immunother (2013) 62:137–147 139
123prepared at weeks 0, 2, and 4; the median cumulative
number [25th, 75th percentile] of TNCs and APCs across
the three doses, pooled over the three studies were
9.70 9 10
9 [6.97 9 10
9, 13.55 9 10
9], and 1.84 9 10
9
[1.27 9 10
9, 2.88 9 10
9].
Antigen-speciﬁc T cells
In the subset of IMPACT patients who were evaluated,
signiﬁcantly greater antigen-speciﬁc T cells, detected by
proliferation and IFNc ELISPOT responses against
Table 1 Subject demographics and baseline disease characteristics
Sipuleucel-T Control Total
D9901
D9902A
IMPACT
(N = 488)
IMPACT Immune
response subset
(N = 160
a)
D9901
D9902A
IMPACT
(N = 249)
IMPACT Immune
response subset
(N = 77
a)
D9901
D9902A
IMPACT
(N = 737)
IMPACT Immune
response subset
(N = 237
a)
Age (years)
Median 72 72 71 70 71 71
Min, Max 47, 91 49, 89 40, 89 40, 87 40, 91 40, 89
Race n (%)
Caucasian 437 (89.5 %) 138 (86.3 %) 229 (92.0 %) 68 (88.3 %) 666 (90.4 %) 206 (86.9 %)
Black or African American 33 (6.8 %) 13 (8.1 %) 10 (4.0 %) 5 (6.5 %) 43 (5.8 %) 18 (7.6 %)
Other 18 (3.7 %) 9 (5.6 %) 9 (3.6 %) 4 (5.2 %) 27 (3.7 %) 13 (5.5 %)
ECOG performance status n (%)
0 393 (80.5 %) 126 (78.8 %) 199 (79.9 %) 65 (84.4 %) 592 (80.3 %) 191 (80.6 %)
1 95 (19.5 %) 34 (21.3 %) 50 (20.1 %) 12 (15.6 %) 145 (19.7 %) 46 (19.4 %)
Gleason sum n (%)
B6 74 (15.2 %) 16 (10.0 %) 31 (12.4 %) 8 (10.4 %) 105 (14.2 %) 24 (10.1 %)
C7 413 (84.6 %) 144 (90.0 %) 217 (87.1 %) 69 (89.6 %) 630 (85.5 %) 213 (89.9 %)
[10 Bone metastases n (%) 211 (43.2 %) 72 (45.0 %) 97 (39.0 %) 34 (44.2 %) 308 (41.8 %) 106 (44.7 %)
Laboratory test results (median, SE)
Serum PSA (ng/mL) 51.5 (23.2) 45.2 (54.7) 46.6 (23.2) 40.8 (22.3) 49.9 (17.2) 42.2 (37.7)
LDH (U/L) 190.0 (4.6) 194.0 (5.4) 187.5 (8.4) 192.0 (6.1) 190.0 (4.2) 193.5 (4.1)
Hemoglobin (g/dL) 12.9 (0.1) 12.6 (0.1) 12.7 (0.1) 12.7 (0.2) 12.9 (0.1) 12.7 (0.1)
Alkaline phosphatase (U/L) 103.0 (12.7) 101.0 (15.9) 104.0 (14.6) 93.0 (38.2) 103.0 (9.8) 100.0 (16.4)
a Included all subjects who had at least one of the three immune response assays measured on at least one visit
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Fig. 1 APC activation was characterized by CD54 upregulation on
pre- and post-culture cells using ﬂow cytometry. The increase in
surface CD54 expression on large CD54
? cells post- versus pre-
culture with PA2024 was expressed as an upregulation ratio of the
average number of molecules on post-culture cells divided by the
average number of molecules on pre-culture cells. C control,
S sipuleucel-T. *P\0.001 for sipuleucel-T versus control. Box plots
represent 25th, 75th percentile range, whiskers represent 1.59 the
interquartile range
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123PA2024, were observed in dose preparations from the
sipuleucel-T group relative to control at weeks 2 and 4, but
not at week 0; the greatest values were observed at week 4
for both assays (Fig. 2). Some sipuleucel-T subjects also
demonstrated responses to PAP that were greater than any
of those observed in the control group and lower in mag-
nitude than the anti-PA2024 responses.
Cytokine/chemokine production during manufacture
Cytokines produced by activated APCs were present in the
culture media of sipuleucel-T, but not control, at weeks 0,
2, and 4 (Fig. 3a). Elevated levels of T-cell activation-
associated cytokines were observed in the culture medium
during the manufacture of the second and third doses
(Fig. 3b). T-cell activation cytokines were not induced
when pre-culture cells were cultured with GM-CSF alone
(Fig. 3c).
Characterization of peripheral immune responses
A positive humoral or cellular immune response to PA2024
and/or PAP in any post-baseline assay was observed in
78.8 % (123/156) of sipuleucel-T subjects compared with
13.2 % (10/76) of control subjects. An immune response to
PA2024 was observed in 78.2 % (122/156) of sipuleucel-T
subjects versus 10.5 % (8/76) of control subjects, and a
response to PAP was observed in 39.5 % (60/152) of
sipuleucel-T subjects versus 5.7 % (4/70) of control sub-
jects (Fig. 4).
Sipuleucel-T treatment generated PA2024- and/or PAP-
speciﬁc humoral responses in a majority of subjects (68 %;
102/151), compared with 3 % (2/70) of control subjects.
Anti-PA2024 and anti-PAP antibody titers were greater in
the sipuleucel-T group compared with control at all post-
baseline time points (P\0.001), with a positive response
still evident 26 weeks after initial treatment in 53.2 %
(PA2024) and 17.7 % (PAP) of subjects (Supplementary
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Fig. 2 Immune responses were evaluated at treatment weeks 0, 2,
and 4 for IMPACT subjects with remaining pre-culture cells.
Antigen-speciﬁc T-cell proliferation was expressed as a stimulation
index, the ratio of tritiated thymidine incorporation due to antigen
stimuli compared to tritiated thymidine incorporation due to media
alone. Antigen-speciﬁc T-cell memory was assessed by IFNc
ELISPOT, with each spot indicating a T cell that secretes IFNc in
response to stimuli, and the number of spots expressed as an integer of
the number of PBMC plated/well of the ELISPOT plate (per 3 9 10
5
PBMC). PBMC, peripheral blood mononuclear cells; PA2024, a
fusion protein comprising PAP fused to granulocyte–macrophage
colony-stimulating factor; PAP, prostatic acid phosphatase; C control;
S sipuleucel-T. *P\0.01 for sipuleucel-T versus control. Box plots
for Stimulation Index represent 25th, 75th percentile range, whiskers
represent 1st and 99th percentile; box plots for IFNc ELISPOT
represent SD, whiskers represent 1.59 SD
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123Figure 2A). The magnitude of PA2024- and PAP-speciﬁc
IgM antibodies peaked at week 6 and remained detectable
through week 26, while anti-PA2024 and anti-PAP IgG
antibodies were detected at week 6 and further increased at
weeks 14 and 26 (Supplementary Figure 2B).
Sipuleucel-T treatment also elicited PA2024- and/or
PAP-speciﬁc cellular responses in a majority of subjects
(60 % [61/102] T-cell proliferation; 48 % [49/102] IFNc
ELISPOT), compared with a positive response in control
subjects of 6 % (3/51) for T-cell proliferation and 13 %
[7/52] for IFNc ELISPOT. PA2024-speciﬁc T-cell prolif-
eration and IFNc ELISPOT were signiﬁcantly greater with
sipuleucel-T at all post-baseline time points (P\0.05;
Supplementary Figure 3), and signiﬁcantly more sipuleu-
cel-T subjects responded to each assay (Fig. 4). The
magnitude of PAP-speciﬁc T-cell proliferation was not
signiﬁcantly different between groups (Supplementary
Figure 3); however, only sipuleucel-T subjects demon-
strated a positive proliferation response to PAP (Fig. 4).
PAP-speciﬁc IFNc ELISPOT results and responder fre-
quency were not signiﬁcantly different between groups at
any time point (Fig. 4; Supplementary Figure 3).
Correlations of overall survival with product
parameters and peripheral immune response
In sipuleucel-T treated subjects, a positive correlation was
observed between OS and cumulative APC activation,
APC count, and TNC count (pooled studies; Fig. 5). These
correlations remained after adjusting for baseline prog-
nostic factors (PSA and LDH) that are independently cor-
related with OS [14]. For a graphical depiction of these
correlations, Kaplan–Meier curves were generated for
sipuleucel-T subjects with cumulative product parameters
greater than versus less than or equal to the median value
(Fig. 5a–c). OS was also signiﬁcantly correlated with the
development of at least one post-baseline peripheral
immune response to PA2024 or PAP [HR = 0.47 (95 %
CI: 0.29, 0.78) P = 0.003; Fig. 5d], to PA2024
[HR = 0.46 (95 % CI: 0.28, 0.76) P = 0.002; Fig. 5e],
and to PAP [HR = 0.53 (95 % CI: 0.31, 0.90) P = 0.019;
Fig. 5f]. The strongest correlation between OS and the
development of a post-baseline immune response to
PA2024 at any time point was observed with antibody
responses [HR = 0.42 (95 % CI: 0.26, 0.67) P\0.001],
while the correlation with IFNc ELISPOT at any time point
approached statistical signiﬁcance [HR = 0.55 (95 % CI:
0.28, 1.08) P = 0.08]; T-cell proliferation response did not
signiﬁcantly correlate with OS.
Discussion
Sipuleucel-T, the ﬁrst autologous cellular immunotherapy
to be FDA-approved for the treatment of cancer, is man-
ufactured from a patient’s own PBMCs obtained during
leukapheresis. The mononuclear cells removed during
leukapheresis constitute only a small percentage of the
body’s total pool of lymphocytes [22–24] and are rapidly
replenished [25] such that median cell counts were within
normal ranges 2, 10, and 22 weeks after the third leuka-
pheresis procedure [26, 27]. The PBMCs are cultured with
the recombinant PAP-GM-CSF fusion antigen (PA2024),
which is processed by APCs and presented as PAP epitopes
to PAP-speciﬁc T cells [18]. The proportion of cell sub-
types remains constant throughout the manufacturing
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Fig. 3 Chemokines and cytokines were measured in available post-
culture supernatants of IMPACT subjects. Sipuleucel-T induced
chemokines associated with APC activation (a) during manufacture of
each dose, whereas cytokines associated with T-cell activation
(b) were predominantly produced during manufacture of the second
and third doses. c Restimulation of pre-culture cells, at each treatment
week, with GM-CSF (Leukine) did not induce T-cell activation
cytokines. C control; S sipuleucel-T. Box plots represent 25th, 75th
percentile range, whiskers represent 1.59 the interquartile range
b
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123process. The data presented here support the proposed
mechanism of action: ex vivo-activated APCs from the ﬁrst
sipuleucel-T infusion engage the immune system in vivo in
a manner similar to a classical vaccine-mediated memory
response, where the ﬁrst infusion primes the immune sys-
tem and subsequent infusions boost the response.
Activation of APCs, as measured by CD54 upregulation,
was evident in the ﬁrst dose (week 0) in PA2024-cultured
cells and further increased in the second (week 2) and third
(week 4) doses. The supposition that the ﬁrst infusion of
activated, antigen-loaded APCs primes T cells in vivo is
supported by evidence of antigen-speciﬁc T-cell prolifer-
ation and IFNc ELISPOT activity in pre-culture cells
obtained at weeks 2 and 4 (but not week 0), as well as the
presence of T-cell activation-associated cytokines in the
second and third doses of sipuleucel-T. While APCs do not
have anamnestic properties, the presence of cytokines
produced by activated T cells, such as TNFa, is known to
further activate APCs and induce the expression of
cytokines associated with APC activation (e.g., IL-1b)[ 28,
29]. Thus, the prime-boost pattern that was also detected
for APC activation and associated cytokines could be due
to signals from antigen-speciﬁc T cells re-stimulated with
antigen during preparation of the second and third doses.
Of note, the fact that re-stimulation of pre-culture cells
with GM-CSF failed to induce cytokines associated with
activated T cells supports the premise that GM-CSF alone
is not responsible for the observed antigen-speciﬁc immune
responses; this is consistent with preclinical ﬁndings [30].
TH1 cytokines (e.g., IFNc, TNFa) in the product were
present at high levels in comparison with IL-4, the classical
marker of TH2 cells, but the presence of TH2 cytokines IL-
5 and IL-13 implies that both TH1 and TH2 cells were
activated in an antigen-speciﬁc manner. This is consistent
with the observation that sipuleucel-T treatment induced
both cellular and humoral responses. Intriguingly, IL-17
was also produced, suggesting the activation of TH17 cells,
a TH subset known to have a pivotal role in mediating
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Fig. 4 Immune responses were determined at baseline (week 0) as
well as 6, 14, and 26 weeks following the ﬁrst product infusion in a
subset of patients enrolled in IMPACT. The percent (SE) of subjects
with positive responses to antigen-speciﬁc antibody (ELISA), mem-
ory IFNc ELISPOT, and T-cell proliferation are summarized. The
positive threshold for antibody response was deﬁned as a titer[400.
The threshold for T-cell proliferation responders was deﬁned as an
SI[12 for the PA2024 antigen and [8 for the PAP antigen. A
positive IFNc ELISPOT response was deﬁned as [10 spots for the
PA2024 antigen and [40 spots for the PAP antigen, per 3 9 10
5
PBMC. *P\0.001 for sipuleucel-T versus control
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123autoimmune responses [31, 32]. In addition, while IL-10
was also detectable, the relative amount of this T-cell-
suppressive cytokine was markedly less than that of cyto-
kines known to drive T-cell expansion, such as IL-2, IFNc,
and TNFa.
These data demonstrate that sipuleucel-T engages the
immune system early in treatment and generates robust and
persistent in vivo antigen-speciﬁc cellular and humoral
immunity. In T-cell proliferative antigen recall assays, a
pertinent measure of immunological responsiveness,
PA2024-speciﬁc responses were present in the majority of
sipuleucel-T-treated subjects with the magnitude of the
response sustained through at least week 26. Furthermore,
the IFNc ELISPOT responses detected in the sipuleucel-T
group at week 26 are indicative of persistent PA2024-
speciﬁc memory T cells [33]. Finally, the development of
early IgM responses followed by isotype switching to IgG
antibody production is characteristic of memory plasma
cell development and suggests the engagement of T cells
and the establishment of long-lasting humoral immunity.
Immune responses to PAP were detectable but were less
frequent and lower in magnitude than responses to the
immunizing antigen (PA2024). Several factors may con-
tribute to these ﬁndings. First, PA2024 was tailored to be
more easily taken up and effectively processed by APCs
and is larger (containing more epitopes) than PAP. Fur-
thermore, the additional epitopes in PA2024 include the
linker between GM-CSF and PAP, a neoepitope that may
be more immunogenic than the epitopes to PAP. Finally, it
should also be noted that tumor antigen-speciﬁc effector T
cells may transit out of the peripheral blood, which is used
as the source of PBMCs for the manufacture of sipuleucel-
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Fig. 5 Overall survival assessed by product characteristics (a, b, c;
Kaplan–Meier survival plots for sipuleucel-T subjects with product
parameters above vs. below the median value; P values from analysis
of each parameter as a continuous measure) and antigen-speciﬁc
immune response (d, e, f; Kaplan–Meier survival plots for sipuleucel-
T responders and non-responders for a subset of IMPACT subjects).
a Cumulative APC activation value [HR = 0.76 (95 % CI: 0.58,
0.99)]. b Cumulative CD54
? cell count [HR = 0.79 (95 % CI: 0.68,
0.93)]. c Cumulative TNC count [HR = 0.71 (95 % CI: 0.59, 0.87)].
d Response to PA2024 or PAP in at least one of the three immune
response assays [HR = 0.47 (95 % CI: 0.29, 0.78)]; e Response to
PA2024 in at least one of the three immune response assays
[HR = 0.46 (95 % CI: 0.28, 0.76)]; f Response to PAP in at least one
of the three immune response assays [HR = 0.53 (95 % CI: 0.31,
0.90)]. HR\1 indicates reduced risk of death with greater cumu-
lative product parameter values (a, b, c). Hazard ratios and 95 %
conﬁdence intervals from analysis of the natural logarithm of each
parameter as a continuous measure in a Cox regression model,
stratiﬁed by study, and adjusted for baseline PSA and LDH. P values
are from analyses with and without adjustment for baseline PSA and
LDH. HR\1 indicates reduced risk of death with presence of an
immune response (d, e, f). Immune responder cohorts were deﬁned as
described in Methods. Hazard ratios and 95 % conﬁdence intervals
from a Cox regression model, adjusted for baseline PSA and LDH.
P values are from analyses with and without adjustment for baseline
PSA and LDH
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123T and for immune monitoring, complicating comparisons
between responses. Nevertheless, the fact that anti-PAP
antibodies were detected in subjects treated with sipuleu-
cel-T when no such antibodies could be identiﬁed in the
pre-treatment specimens and that PAP-speciﬁc T-cell
responders were observed only in the sipuleucel-T group
supports the supposition that sipuleucel stimulates antigen-
speciﬁc B- and T-cell responses that target prostate cancer.
The positive correlation observed between key product
parameters, such as APC activation, and OS suggests that
the broad engagement of the immune system by sipuleucel-
T contributes to the survival beneﬁt associated with therapy.
Moreover, patients who developed a peripheral immune
response to sipuleucel-T had improved OS. The strongest
relationship between prolonged OS and long-term immune
response was observed with PA2024-speciﬁc antibody and
IFNc ELISPOT responses. The absence of a signiﬁcant
correlation between OS and T-cell proliferation may be due
to the non-speciﬁc nature of the T-cell proliferation assay
(i.e., it does not distinguish between biologically functional
vs.non-functionaleffectormemorycells).Assuch,theIFNc
ELISPOT assay, which is a direct measure of the estab-
lishment offunctional antigen-speciﬁc memory Tcells, may
be a better indicator of relevant immune response.
Limitations of this study include the availability of
immune response data for only a subset of patients, and the
post hoc correlative nature of the analyses. In addition, the
correlations between immune parameters and increased OS
could result from healthier subjects with an improved
probability of survival being more likely to generate robust
immune responses. However, the persistence of the corre-
lations between these immune markers and OS following
adjustment for baseline prognostic factors argues against
this hypothesis, as does the fact that humoral recall
response to tetanus did not change following treatment and
was not different between the control and treatment groups
(data on ﬁle; Dendreon). In addition, prior studies dem-
onstrated no differences in baseline T-cell proliferation
response to inﬂuenza between patients who did or did not
subsequently develop an immune response to PAP [34].
Similarly, previous work in follicular lymphoma failed to
demonstrate a correlation between anti-idiotype immune
response in response to immunization and baseline prog-
nostic factors or the ability to respond to KLH [35].
In summary, the data presented here demonstrate that ex
vivo APC activation with sipuleucel-T induces a robust and
long-lived in vivo immune response proﬁle characteristic
of immunological memory. Both cellular and humoral
responses were evident, and the response status of subjects
as well as the magnitude of the immune response correlated
with OS. These data are consistent with sipuleucel-T’s
intended mechanism of action: to generate antigen-speciﬁc
immune responses that target prostate cancer. A recent
study of sipuleucel-T administered prior to radical prosta-
tectomy demonstrating increases in T cells at the tumor
interface compared to the pre-treatment biopsy [36] pro-
vides further evidence in support of this mechanism of
action. Given the increasing availability of novel immu-
nomodulatory agents, combination studies with sipuleucel-
T are warranted; augmentation of the immune parameters
described herein would provide a strong rationale for larger
studies to demonstrate increased clinical efﬁcacy.
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